Menu
Search
|

Menu

Close
X

MacroGenics Inc MGNX.OQ (NASDAQ Stock Exchange Global Select Market)

22.27 USD
+0.04 (+0.18%)
As of Jul 20
chart
Previous Close 22.23
Open 22.21
Volume 74,352
3m Avg Volume 142,087
Today’s High 22.37
Today’s Low 22.07
52 Week High 32.57
52 Week Low 14.36
Shares Outstanding (mil) 36.80
Market Capitalization (mil) 659.43
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.90 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
5
FY17
158
FY16
92
FY15
101
EPS (USD)
FY18
-1.341
FY17
-0.622
FY16
-1.728
FY15
-0.578
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
54.58
5.73
Price to Book (MRQ)
vs sector
2.84
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.48
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-49.45
14.61
Return on Equity (TTM)
vs sector
-52.35
16.34

EXECUTIVE LEADERSHIP

Paulo Costa
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Scott Koenig
President, Chief Executive Officer, Director, Since 2001
Salary: $535,600.00
Bonus: $240,000.00
James Karrels
Chief Financial Officer, Senior Vice President, Secretary, Since 2008
Salary: $344,400.00
Bonus: $105,111.00
Ezio Bonvini
Senior Vice President - Research, Chief Scientific Officer, Since 2016
Salary: $369,627.00
Bonus: $115,067.00
Atul Saran
Senior Vice President, General Counsel, Since 2014
Salary: $228,867.00
Bonus: $88,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

9704 Medical Center Dr
ROCKVILLE   MD   20850-3343

Phone: +1301.2515172

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.

SPONSORED STORIES